Variant antibodies that bind OX40
The present disclosure provides variant anti-OX40 antibodies that mimic the activity of OX40L by behaving as an agonist against receptor OX40 to enhance T cell clonal expansion and differentiation. The variant anti-OX40 antibodies exhibit improved binding affinity for OX40 and improved agnostic activity, compared to a wild type anti-OX40 antibody (wild type 2B4 clone) from which the variant clones are derived. The variant anti-OX40 antibodies specifically bind OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, stimulate proliferation of effector T cells in the presence of regulatory T cells, and stimulate production of at least one cytokine from effector T cells.
1. An anti-OX40 antibody, or an antigen binding fragment thereof, that binds to an OX40 epitope, wherein the anti-OX40 antibody or antigen binding fragment thereof comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 9, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO 7.
2. The anti-OX40 antibody, or antigen binding fragment thereof, of claim 1 , wherein the anti-OX40 antibody is an IgG isotype.
3. The anti-OX40 antibody, or antigen binding fragment thereof, of claim 1 , comprising an Fab, an Fab′, an F(ab′) 2 , an Fv, a domain antibody, a single chain antibody, a diabody, a triabody, or a tetrabody.
4. The anti-OX40 antibody, or antigen binding fragment thereof, of claim 1 , comprising a polypeptide comprising the anti-OX40 antibody or antigen-binding fragment thereof.
5. The anti-OX40 antibody, or antigen binding fragment thereof, of claim 1 , wherein the anti-OX40 antibody or antigen binding fragment thereof binds to the OX40 epitope with a K d less than 1×10 −8 M.
6. A method for inducing proliferation of effector T cells, comprising: contacting the effector T cells with the anti-OX40 antibody, or antigen binding fragment thereof, of claim 1 .
7. The method of claim 6 further comprising: detecting an increase in proliferation of the effector T cells.
8. The method of claim 6 , further comprising contacting the effector T cells with CD3.
9. The method of claim 6 , wherein the effector T cells are CD4+ effector T cells.
10. A method for inducing effector T cells to increase production of at least one cytokine, comprising: contacting effector T cells with the anti-OX40 antibody, or antigen binding fragment thereof, of claim 1 .
11. The method of claim 10 , further comprising: detecting an increase in production of the at least one cytokine by the effector T cells.
12. The method of claim 10 , wherein the at least one cytokine is selected from a group consisting of gamma-interferon, IL-2, IL-4 and tumor necrosis factor (TNF).
13. The method of claim 10 , further comprising contacting the effector T cells with CD3.
14. The method of claim 10 , wherein the effector T cells are CD4+ effector T cells.
15. A method for inducing proliferation of effector T cells (Teff) in the presence of regulatory T cells (Treg), comprising: contacting the effector T cells and the regulatory T cells with the anti-OX40 antibody, or antigen binding fragment thereof, of claim 1 .
16. The method of claim 15 , further comprising detecting an increase in proliferation of the effector T cells.
17. The method of claim 15 , further comprising contacting the effector T cell and the regulatory T cell with CD3.
18. The method of claim 15 , wherein the effector T cells express CD25.
19. The method of claim 15 , wherein the effector T cells produce at least one cytokine selected from a group consisting of IL-2, IL-4 and INFγ.